title: Additive effects of cepharanthin in CDDP/hyperthermia combination therapy against transplantable human esophageal cancer in nude mice.
abstract: OBJECTIVE
  Additive effects of cepharanthin in CDDP/hyperthermia combination therapy were evaluated.
  
  
  METHODS
  Nude mice bearing a transplantable human esophageal cancer (ES0-2), classified histologically as a moderately differentiated squamous cell carcinoma, were treated with cepharanthin (20 mg/kg IP) in addition to cis-diamminedichloroplatinum(II) (CDDP; 4 mg/kg IP) and/or hyperthermia at 42 degrees C for 30 min, to determine the additive effects of cepharanthin. Furthermore, effects of cepharanthin on intratumoral concentration of CDDP were evaluated.
  
  
  RESULTS
  Cepharanthin itself did not have an anti-tumor effect. This agent did not enhance the anti-tumor effect of CDDP alone, but enhanced the anti-tumor effects of both 42 degrees C hyperthermia alone, and combination therapy with CDDP and 42 degrees C hyperthermia. The concentration of CDDP in the tumors treated by 42 degrees C hyperthermia was slightly higher than in nonheated tumors. Cepharanthin did not affect the intratumoral concentration of CDDP, irrespective of whether hyperthermia was applied.
  
  
  CONCLUSIONS
  Cepharanthin enhanced the effect of CDDP/hyperthermia combination therapy through thermoenhancing effect.
authors.affiliation: First Department of Surgery, Nara Medical University, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Yano
authors.forename: K
authors.initials: K
authors.lastname: Nakatani
authors.forename: A
authors.initials: A
authors.lastname: Watanabe
authors.forename: H
authors.initials: H
authors.lastname: Sawada
authors.forename: Y
authors.initials: Y
authors.lastname: Yamada
authors.forename: H
authors.initials: H
authors.lastname: Nakano
authors.forename: T
authors.initials: T
authors.lastname: Ohnishi
mesh_terms: D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D044182:Benzylisoquinolines; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000628:therapy*; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D052117:Benzodioxoles
chemical_list: D000470:Alkaloids; D044182:Benzylisoquinolines; D002945:Cisplatin; C006947:cepharanthine; D052117:Benzodioxoles